Search effective ways solve problem struggle bacterial infectious pathology

Abstract


Discoveries of the late 20, early 21 century allowed deciphering genomes of many organisms including the genomes of the pathogenic and opportunistic bacteria. These discoveries provided a hope for quick solutions for controlling of the bacterial infections. However at present it is obvious that routine approaches based on antibiotic therapy do not have a bright future. Construction of new drugs or vaccines based on the knowledge of bacterial genomics does not look as easy as before due to many reasons including the problems caused by complexity of human microbiota. In the review article the author argue that old concepts of clinical microbiology based on the division of bacteria into symbionts and the parasites require revision.

A N Suvorov

Email: Alexander_suvorov1@hotmail.com

  1. Бухарин О.В. Персистенция патогенных бактерий. Екатеринбург: Медицина.С. 366.
  2. Грабовская К.Б., Леонтьева Г.Ф., Мерингова Л.Ф. и соавт. Протективные свойства некоторых поверхностных рекомбинантных полипептидов стрептококков группы В // ЖМЭИ. 2007. № 5. С. 44-51.
  3. Дитина М.A., Мерингова Л.Ф., Леонтьева и соавт. Сравнительное изучение конъюгированной и комбинированной экспериментальных вакцин против стрептококков группы В // Журн. микробиол., эпидемиол. и иммунобиол. 2009. № 1. С. 37-41.
  4. Мечников И.И. Этюды оптимизма. М.: Наука, 1964. 339 с.
  5. Сидоренко С.В. Инфекционный процесс как «диалог» между хозяином и паразитом // Клин. Микробиол. и антимикроб. химиотер. 2001. Т. 3. № 4. С.301-315.
  6. Суворов A.H., Савичева А.М., Глушанова A.B. и соавт. Анализ клинических штаммов стрептококков группы В на наличие генов потенциальных адгезинов, локализованных на островах патогенности // Журн. акушерства и женских болезней. 2005. LV. С. 50-56.
  7. Ткаченко Е.И., Суворов А.Н. Дисбиоз кишечника: руководство по диагностике и лечению. СПб.: ИнформМед. 2009. 276 с.
  8. Тотолян A.A., Суворов A.H., Дмитриев A.B. Стрептококки группы В в патологии человека: монография. СПб.: Человек, 2009. 211с.
  9. Шендеров Б.А. Медицинская микробная экология и функциональное питание. T. II: Социально-экологические и клинические последствия дисбаланса микробной экологии человека и животных. М.: ГРАНТь, 1998.416 с.
  10. Ahmed N.A., Petersen F.C., Scheie A.A. AI-2/LuxS is involved in increased biofilm formation by Streptococcus intermedius in the presence of antibiotics // Antimicrob. Agents and Chemother. 2009. Vol. 53. № 10. P. 4258-4263.
  11. Allen N.E., Hobbs J.N.Jr., Nicas T.I. Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic // Antimicrob. Agents Chemother. 1996. Vol. 40 (10). P. 2356-2362.
  12. Arbeit R.D., Roberts J.A. Forsythe et al. Safety and Efficacy of PTK. 0796: Results of the Phase 2 Study in complicated skin and skin structure infections following IV' and oral step-down therapy (L-1515b); 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (1CAAC) and the Infectious Disease Society of America (IDSA) 46th Annual Meeting: Oct. 25-28. Washington DC. 2008.
  13. Anderson R.M. и May R.M. Coevolution of hosts and parasites // Parasitology. 1982. Vol. 85. P. 411-426.
  14. Arciola C.R., Speziale P., Montanaro L. Perspectives on DNA vaccines. Targeting staphylococcal adhesins to prevent implant infections // Int. J. Artif. Organs. 2009. Vol. 32(9). P. 635-641.
  15. Brown E.L., Dumitrescu O., Thomas D. The Panton-Valentine Ieukocidin vaccine protects mice against lung and skin infections caused by Staphylococcus aureus USA300 // Clin. Microbiol. Infect. 2009. Vol. 15. P. 156-164.
  16. Brüssow H., Canchaya C., Hardt W.D. Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion // Microbiol, and Molecular Biol. Rev. 2004. Vol. 68. № 3. P. 560-602.
  17. Buccato S., Maione D., Rinaudo C.D. et al. Use of Lactococcus lactis expressing pili from group В Streptococcus as a broad-coverage vaccine against streptococcal disease // J. Infect. Dis. 2006. Vol. 1. № 194. P. 331-340.
  18. Clark J.R., March J.B. //Trends in Biotechnol. 2006. Vol. 24. P. 212-218.
  19. Cheng Q., Nelson D., Zhu S., Fischetti V.A. Removal of group В streptococci colonizing the vagina and oropharynx of mice with a bacteriophage lytic enzyme // Antimicrob. Agents Chemother. 2005. Vol. 49. P. 111-117.
  20. D'Herelle F. On an invisible microbe antagonistic toward dysenteric bacilli: brief note by Mr. F. D'Herelle, presented by Mr. Roux // Les Comptes rendus de l'Académie des Sciences. 1917. Vol. 165. P. 373-375.
  21. Devasahayam D., Scheid W.M., Hoffman P.S. Newer Antibacterial Drugs for a New Century // Exp. Opin. Investig. Drugs. 2010. Vol. 19(2). P. 215-234.
  22. Fischetti V.A., Nelson D. and Schuch R. Reinventing phage therapy: are the parts greater than the sum? // Nature Biotechnol. 2006. Vol. 24. P. 1508-1511.
  23. Geisinger E., Muir T.W., Novick R.P. Agr receptor mutants reveal distinct modes of inhibition by staphylococcal autoinducing peptides // Proc. Natl. Acad. Sei. USA. 2009. Vol. 106. P. 1216-1221.
  24. George E.A., Muir T.W. Molecular mechanisms of agr quorum sensing in virulent staphylococci // Chembiochem. 2007. Vol. 8. P. 847-855.
  25. Gordon D.M., Oliver E., Littlefield-Wyer J. The diversity of bacteriocins in Gram-negative bacteria / Riley M.A., Chavan M. (eds.) // Bacteriocins: ecology and evolution. Berlin: Springer, 2007. P. 5-18.
  26. Gov Y., Bitler A., Dell’Acqua G. и et al. RNAIII inhibiting peptide (RIP), a global inhibitor of Staphylococcus aureus pathogenesis: structure and function analysis // Peptides. 2001. Vol. 22. P. 1609-1620.
  27. Hak E., Grobbee D.E., Sanders Е.А. et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults // Neth. J. Med. 2008. Vol. 66 (9). P. 378-383.
  28. Hausdorff W.P., Hoet B., Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? // BMC Pediatr. 2010. Vol.
  29. № 10. P. 4-15.
  30. Jones R.N., Huynh H.K., Bicdenbach D.J. et al. Doripenem (S-4661 ), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations //J. Antimicrob. Chemother. 2004. Vol. 54 (1). P. 144-154.
  31. Kandulski A., Selgrad M., Malfertheiner P. Helicobacter pylori infection: a clinical overview // Dig. Liver. 2008. Vol. 40. P. 619-626.
  32. Kuijl C., Savage N.D., Marsman M. et al. Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1 // Nature. 2007. Vol. 29. № 450 (7170). P. 725-730.
  33. Livermore D.M., Warner M., Mushtaq S. et al. In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci // Antimicrob. Agents Chemother. 2007. Vol. 51 (3). P. 1112-1114.
  34. Lunde C.S., Hartouni S.R., Jane J.W. et al. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II // Antimicrob. Agents Chemother. 2009. Vol. 53 (8). P. 3375-3383.
  35. McShan W.M., Ferretti J.J., Karasawa T. et al. Analysis of the Complete Genome Sequence of NZ131, a Highly Transformable Nephritogenic M49 Strain of Streptococcus pyogenes // J. Bacteriol. 2008. Vol. 190. P. 7773-7785.
  36. Maisey H.C., Quach D., Hensler M.E. et al. A group В streptococcal pilus protein promotes phagocyte resistance and systemic virulence // FASEB J. 2008. Vol. 22 (6). P. 1715-1724.
  37. Mbulaiteye S.M., Hisada M., El-Omar E.M. Helicobacter Pylori associated global gastric cancer burden //Front. Biosci. 2009. Vol. 14. P. 1490-1504.
  38. Miao E.A., Miller S.I. Bacteriophages in the evolution of pathogen-host interactions // Proc. Natl. Acad. Sei. USA. 2004. Vol. 96. P. 9452-9454.
  39. Njoroge J., Sperandio V. Jamming bacterial communication: New approaches for the treatment of infectious diseases // EMBO Mol. Med. 2009. Vol. 1 (4). P. 201-210.
  40. Okinaka R., Pearson T., Keim P. Anthrax, but Not Bacillus anthracis? // PLoS Pathog. 2006. Vol. 2 (11). el 22.
  41. Olson M.W., Ruzin A., Feyfant E. et al. Functional, biophysical, and structural bases for antibacterial activity of tigecycline // Antimicrob. Agents Chemother. 2006. Vol. 50 (6). P. 2156-2166.
  42. Peterson M.M., Mack J.L., Hall P.R. et al. Apolipoprotein В is an innate barrier against invasive Staphylococcus aureus infection // Cell Host Microbe. 2008. Vol. 4. P. 555-566.
  43. Piva A., Casadei G. Use of bacteriocin for the amelioration of digestive functionality // USA Patent. 20060233777-2006.
  44. Pritchard D.G., Dong S., Baker J.R., Engler J.A. The bifunctional peptidoglycan lysin of Streptococcus agalactiae bacteriophage B30 // Microbiology. 2004. Vol. 150. P. 2079-2087.
  45. Projan S.J. Why is big Pharma getting out of antibacterial drug discovery? // Curr. Opin. Microbiol. 2003. Vol. 6 (5). P. 427-430.
  46. Ragle B.E., Wardenburg В. J. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia // Infect. Immunol. 2009. Vol. 77(7). P. 2712-2718.
  47. Sand J., Nordback I. Probiotics in severe acute pancreatitis// Lancet. 2008. Vol. 371. P. 634-635.
  48. Shortridge V.D., Zhong P., Cao Z. et al. Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci // Antimicrob. Agents Chemother. 2002. Vol. 46 (3). P. 783-786.
  49. Shaw K.J., Poppe S., Schaadt R. et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains // Antimicrob. Agents Chemother. 2008. Vol. 52 (12). P. 4442-4447.
  50. Shinefield H.R. Use of a conjugate polysaccharide vaccine in the prevention of invasive staphylococcal disease: is an additional vaccine needed or possible? // Vaccine. 2006. Vol. 12. № 24 (Suppl. 2):S2. P. 65-69.
  51. Steer A.C., Batzloff M.R., Mulholland K., Carapetis J.R. Group A streptococcal vaccines: facts versus fantasy // Curr. Opin. Infect. Dis. 2009. Vol. 22 (6). P. 544-552.
  52. Su Z., Honek J.F. Emerging bacterial enzyme targets // Curr. Opin. Investing. Drugs. 2007. Vol. 8 (2). P. 140- 149.
  53. Suvorov A.N., Polyakova E.M., McShan W.M., Ferretti J.J. Bacteriophage content of M49 strains of Streptococcus pyogenes // FEMS Microbiol. Lett. 2009. Vol. 294. № 1. R 9-15.
  54. Tormo M.A., Ferrer M.D., Maiques E. et al. Staphylococcus aureus pathogenicity island DNA is packaged in particles composed of phage proteins // J. Bacteriol. 2008. Vol. 190 (7). P. 2434-2440.
  55. Veiga-Crespo P., Barros-Velázquez J., Villa T. What can bacteriophages do for us? / Communicating Current Research and Educational Topics and Trends in Applied Microbiology // FORMATEX. 2007. P. 885-893.
  56. Wang I.N., Smith D.L., Young R. Holins: the protein clocks of bacteriophage infections //Ann. Rev. Microbiol. 2000. Vol. 54. P. 799-825.
  57. Woodford N., Wareham D.W. Tackling antibiotic resistance: a dose of common antisense? // J. Antimicrob. Chemother. 2009. Vol. 63. P. 225-229.
  58. Xiong L., Kloss P., Douthwaite S. et al. Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action // J. Bacteriol. 2000. Vol. 182 (19). P. 325-331.
  59. Yenrtolenko E., Suvorov A., Chemysh A. et al. Antagonistic activity of Enterococcus faecium L3 against different groups of pathogenic streptococci // Streptococci New Insight into an Old Enemy. 2006. P. 363-366.
  60. Yu Y., Zhao X., Lee L.J., Lee R.J. Targeted delivery systems for oligonucleotide therapeutics // AAPS J. 2009. Vol. 11№ 1.Р. 195-203.

Views

Abstract - 19

PlumX

Refbacks

  • There are currently no refbacks.

Copyright (c) 2010 Suvorov A.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.